Lemmon Co.'s injectable diazepam labeling
Company said that validation work on its labeling process for diazepam syringes will be completed in "the next day or so." FDA is currently conducting a GMP inspection at Lemmon, which follows a recall in June involving 44,470 diazepam syringes. A number of the syringes lacked immediate container labels ("The Pink Sheet" July 3, T&G-17). In December, a recall was initiated for the same reason. According to an Aug. 8 FDA reg letter, Lemmon made corrections to prevent a recurrence of unlabeled syringes after the first recall. However, FDA said that it will not approve drug applications until it is determined through reinspection that "adequate corrective action has been taken".
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.